Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Wednesday 27 Auguest 1997.
"Wyeth-Ayerst will be an excellent partner for us in these countries," said Charles A. Baker, Chairman and Chief Executive Officer of The Liposome Company. "They have a strong presence in the hospital market, and excellent skills and experience in the oncology and infectious disease sectors, that will enable them to market ABELCET effectively. France and Italy are two of the largest pharmaceutical markets in Europe and represent great opportunities to increase our international sales of ABELCET."
"ABELCET will be an important addition to our product portfolio in Europe, where Wyeth-Ayerst enjoys a leadership position in the hospital-based pharmaceutical market," said Bernard Poussot, President, Wyeth-Ayerst International. "Preparations to launch the product in September are underway, and we look forward to the same positive physician acceptance for this product in France and Italy as it has experienced elsewhere."
Seventeen countries have approved ABELCET for various indicated uses. ABELCET is the only lipid based amphotericin B product to have gained approval in France. The companies have indicated that they are discussing possible collaborations in other international markets.
The major types of systemic fungal infections are candidiasis, aspergillosis and cryptococcal meningitis. The fungi that cause these infections are normally controlled and disposed of by the body's healthy immune system . However, patients with suppressed immune systems, most often resulting from the therapies for cancer and bone marrow transplants, as well as patients with AIDS can lose the ability to combat these fungi.
Candida species are the most common type of invasive fungal infections, representing approximately 70 percent of all such infections. Fatality rates in candida infections are between 30 and 40 percent.
Aspergillosis , while occurring less frequently, is a significant threat as fatality rates for this disease are approximately 90 percent. Cryptococcal meningitis is a disease that frequently strikes patients with AIDS.
Wyeth-Ayerst International is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines, and anti-infectives and oncology products. American Home Products is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs and over-the-counter medications. It is also a global leader in vaccines, biotechnology, agricultural products, animal health care and medical devices.
The Liposome Company is a broad-based biopharmaceutical company developing and marketing products based on its knowledge of lipid technology. ABELCET (Amphotericin B Lipid Complex Injection) is marketed in the U.S. and other countries for the treatment of severe systemic fungal infections. TLC D-99 and other products are being developed to treat various cancers. Research is being conducted on new cancer therapies and biologically active lipids that may have therapeutic applications.
Except for historical information, this press release contains forward- looking statements that involve risks and uncertainties including but not limited to statements regarding future growth in sales of ABELCET, the possibility of finalizing agreements for other markets, and the likelihood that TLC D-99 or any other product can be successfully developed and commercialized. While these statements reflect the Company's best current judgment, they are subject to risks and uncertainties that could cause actual results to vary, including the risk factors identified in the Registration Statement on Form S-3 dated June 9, 1997 and in the Company's subsequent SEC filings.
This release is also available at http://www.lipo.com
CONTACT: Brooks Boveroux, Vice President of The Liposome Company, 609-452-7060; or media: Renee Solano, ext. 227, or investors: Barbara Lindheim, ext. 237, both of Noonan Russo Communications, 212-696-4455, for Liposome.
Copyright (c) 1997/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
970827
PR970820
Copyright © 1997 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .